92 related articles for article (PubMed ID: 3069842)
1. Propioxatins A and B, new enkephalinase B inhibitors. IV. Characterization of the active site of the enzyme using synthetic propioxatin analogues.
Inaoka Y; Naruto S
J Biochem; 1988 Nov; 104(5):706-11. PubMed ID: 3069842
[TBL] [Abstract][Full Text] [Related]
2. Enkephalin-degrading dipeptidylaminopeptidase: characterization of the active site and selective inhibition.
Chérot P; Devin J; Fournié-Zaluski MC; Roques BP
Mol Pharmacol; 1986 Oct; 30(4):338-44. PubMed ID: 3531805
[TBL] [Abstract][Full Text] [Related]
3. Propioxatins A and B, new enkephalinase B inhibitors. III. Total synthesis of propioxatin A.
Inaoka Y; Takahashi S; Sato S
J Antibiot (Tokyo); 1986 Oct; 39(10):1382-5. PubMed ID: 3781908
[TBL] [Abstract][Full Text] [Related]
4. Effect of various enkephalin analogs and dipeptides on the enzymatic activity of enkephalinase B isolated from calf-brain striatum.
van Amsterdam JG; van Buuren KJ; Koomen AP; Soudijn W
Life Sci; 1986 Mar; 38(12):1111-8. PubMed ID: 3515091
[TBL] [Abstract][Full Text] [Related]
5. Propioxatins A and B, new enkephalinase B inhibitors. I. Taxonomy, fermentation, isolation and biological properties.
Inaoka Y; Tamaoki H; Takahashi S; Enokita R; Okazaki T
J Antibiot (Tokyo); 1986 Oct; 39(10):1368-77. PubMed ID: 3536826
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of enkephalinase B inhibitors, and their activity on isolated enkephalin-degrading enzymes.
Van Amsterdam JG; Van Buuren KJ; Blad MW; Soudijn W
Eur J Pharmacol; 1987 Mar; 135(3):411-8. PubMed ID: 3556201
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of calf-brain enkephalinase A and B.
van Amsterdam JG; van Buuren KJ; de Jong AM; Soudijn W
Life Sci; 1983; 33 Suppl 1():109-12. PubMed ID: 6363851
[TBL] [Abstract][Full Text] [Related]
8. Purification and characterization of enkephalinase B from rat brain membrane.
Inaoka Y; Tamaoki H
Biochim Biophys Acta; 1987 Jul; 925(1):27-35. PubMed ID: 3297170
[TBL] [Abstract][Full Text] [Related]
9. Differential recognition of "enkephalinase" and angiotensin-converting enzyme by new carboxyalkyl inhibitors.
Fournié-Zaluski MC; Soroca-Lucas E; Waksman G; Llorens C; Schwartz JC; Roques BP
Life Sci; 1982 Dec; 31(26):2947-54. PubMed ID: 6298535
[TBL] [Abstract][Full Text] [Related]
10. Bidentate peptides: highly potent new inhibitors of enkephalin degrading enzymes.
Bouboutou R; Waksman G; Devin J; Fournié-Zaluski MC; Roques BP
Life Sci; 1984 Aug; 35(9):1023-30. PubMed ID: 6088932
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR
Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
13. Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors.
Fournie-Zaluski MC; Lucas E; Waksman G; Roques BP
Eur J Biochem; 1984 Mar; 139(2):267-74. PubMed ID: 6321177
[TBL] [Abstract][Full Text] [Related]
14. Propioxatins A and B, new enkephalinase B inhibitors. II. Structural elucidation.
Inaoka Y; Takahashi S; Kinoshita T
J Antibiot (Tokyo); 1986 Oct; 39(10):1378-81. PubMed ID: 3781907
[TBL] [Abstract][Full Text] [Related]
15. Labelling and exploration of the active site of enkephalinase (EC 3.4.24.11) in kidney membranes with [3H]thiorphan as ligand.
De la Baume S; Schwartz JC
Eur J Pharmacol; 1988 Apr; 149(1-2):121-9. PubMed ID: 3165067
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human leukocyte elastase by N-substituted peptides containing alpha,alpha-difluorostatone residues at P1.
Skiles JW; Miao C; Sorcek R; Jacober S; Mui PW; Chow G; Weldon SM; Possanza G; Skoog M; Keirns J
J Med Chem; 1992 Dec; 35(26):4795-808. PubMed ID: 1479581
[TBL] [Abstract][Full Text] [Related]
17. Phosphoramidate peptide inhibitors of human skin fibroblast collagenase.
Kortylewicz ZP; Galardy RE
J Med Chem; 1990 Jan; 33(1):263-73. PubMed ID: 2153207
[TBL] [Abstract][Full Text] [Related]
18. Cleavage efficiency of the novel aspartic protease yapsin 1 (Yap3p) enhanced for substrates with arginine residues flanking the P1 site: correlation with electronegative active-site pockets predicted by molecular modeling.
Olsen V; Guruprasad K; Cawley NX; Chen HC; Blundell TL; Loh YP
Biochemistry; 1998 Mar; 37(9):2768-77. PubMed ID: 9485427
[TBL] [Abstract][Full Text] [Related]
19. Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan.
Roques BP; Lucas-Soroca E; Chaillet P; Costentin J; Fournié-Zaluski MC
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3178-82. PubMed ID: 6304695
[TBL] [Abstract][Full Text] [Related]
20. Substrate-related potent inhibitors of brain metalloendopeptidase.
Orlowski M; Michaud C; Molineaux CJ
Biochemistry; 1988 Jan; 27(2):597-602. PubMed ID: 3162384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
